Tactiva Therapeutics Inc., of Buffalo, N.Y., secured a $35 million series A financing and closed on the first tranche. Proceeds will be used to advance the clinical development of dual enhanced adoptive cell therapy (DEACT) platform for the treatment of multiple myeloma and several solid tumor type cancer indications. The financing was led by Panacea Ventures and included Vi Ventures and Efung Capital.